The Patent Finder

Terms ending in 2027

Aventis Pharma S.A.

Every in-force patent on Aventis Pharma S.A.'s record whose computed term ends in 2027, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleHolderStatusExpiresConfidence
US 7,935,819Novel Cyclic Urea Derivatives, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors
In force
 · High confidence
Aventis Pharma S.A.In forceHigh confidence
US 7,674,795Novel Fluorene Derivatives, Composition Containing Said Derivatives and the Use Thereof
In force
 · High confidence
Aventis Pharma S.A..In forceHigh confidence
US 8,058,2907-Substituted Aza-Indazoles, Compositions Containing Same, Production Method and Use Thereof
In force
 · High confidence
Aventis Pharma S.A..In forceHigh confidence
US 8,608,961Method for Affinity Chromatography of Antithrombin III
In force
 · High confidence
Sanofi Mature IPIn forceHigh confidence
US 8,211,676Cholesterol-Producing Yeast Strains and Uses Thereof
In force
 · High confidence
Euroapi FranceIn forceHigh confidence
5 of 5 patents shown. Soonest term end first, then patent number.
3 of these are in force and held by Aventis Pharma S.A..
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited